March 7, 2025
Clinical trials that support the development of new and innovative therapies and healthcare delivery are fundamentally supported by separate infrastructures, processes, and objectives. This comes with unique sets of capabilities, staffing, regulations, data platform systems, and incentives. But patients could be better served by a future that breaks with the status quo and unlocks the…
Explore
March 4, 2025
The 2025 SCOPE Summit brought together industry leaders to explore integrating real-world data into clinical trials, focusing on pragmatic trials as a transformative approach. Key discussions revolved around regulatory initiatives, innovative trial designs, and operational strategies to enhance the applicability of clinical research in real-world settings. The summit highlighted the potential of pragmatic trials to bridge the…
Explore
February 25, 2025
A panel of experts from inside several major pharma companies discussed regulatory initiatives around pragmatic trials in depth at the recent Summit for Clinical Trial Ops Executives (SCOPE). “I got a fever and the only prescription is more pragmatic trials,” quipped Henry Wei, M.D., head of development innovation at Regeneron and a major fan of TransCelerate’s…
Explore
February 5, 2025
The growing convergence between clinical research and clinical care—and ways the second Trump administration will be encouraging and supporting movement in that direction—was the topic of the opening keynote presentation made at this week’s Summit for Clinical Ops Executives (SCOPE) in Orlando. It was presented as an informal but informative dialogue between Janice Chang, CEO of TransCelerate…
Explore
February 3, 2025
This year’s SCOPE conference in Orlando kicked off with a keynote address from Janice Chang, CEO, TransCelerate Biopharma, and Mark McClellan, MD, PhD, director, Duke-Margolis Institute for Health Policy, Former Commissioner, FDA. Titled “Fast Forward to 2035: What Success Could Look Like in Converging Clinical Research and Care—And How to Get There”, the duo discussed…
Explore
